Revolution Medicines registers Phase 3 zoldonrasib trial for RAS G12D-mutated NSCLC

Revolution Medicines has a new Phase 3 trial registration for its RAS(ON) inhibitor zoldonrasib.

• The trial evaluates zoldonrasib, an investigational RAS(ON) inhibitor, combined with pembrolizumab and platinum-based chemotherapy against placebo plus the same regimen in patients with metastatic non-squamous RAS G12D-mutated NSCLC.¹ The study, called RASolve 308, is designed to enroll 430 participants¹ and is currently recruiting¹ at one site in the United States, in Plantation, Florida¹. The primary outcome is progression-free survival, defined as time from randomization to disease progression or death from any cause¹.